A Single-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8504 Monotherapy in Anti-Retroviral Therapy (ART)-Naïve, HIV-1 Infected Patients
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2017
At a glance
- Drugs MK 8504 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 01 Aug 2017 Last checked against ClinicalTrials.gov record.
- 27 Jul 2017 Planned initiation date changed from 14 Jul 2017 to 8 Aug 2017.
- 24 Jun 2017 New trial record